Diamyd Medical’s major owners fully subscribe for their share of a rights issue
02 févr. 2016 02h30 HE
|
Diamyd Medical AB (publ)
Not for release, publication or distribution, directly or indirectly, in the
United States, Canada, Australia, Hong Kong, Japan, New Zealand, Singapore,
Switzerland, Singapore or South Africa.
Diamyd...
Diamyd Medical implements aggressive rights issue
27 janv. 2016 07h40 HE
|
Diamyd Medical AB (publ)
Not for release, publication or distribution, directly or indirectly, in the
United States, Canada, Australia, Hong Kong, Japan, New Zealand, Singapore,
Switzerland, Singapore or South Africa.
Diamyd...
Diamyd Medical genomför offensiv företrädesemission
27 janv. 2016 02h30 HE
|
Diamyd Medical AB (publ)
Detta pressmeddelande får inte offentliggöras, publiceras eller distribueras,
vare sig direkt eller indirekt, i eller till USA, Kanada, Australien, Hongkong,
Japan, Nya Zeeland, Schweiz, Singapore...
Diamyd Medical CEO proposed as new Chairman for Cellaviva AB
22 janv. 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced
that its CEO, Anders Essen-Möller is proposed as new Chairman of the Board of
Cellaviva AB at Cellaviva’s Annual General...
Diamyd Medicals vd föreslås som ny ordförande i Cellaviva AB
22 janv. 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar att Diamyd
Medicals vd Anders Essen-Möller föreslås som ny styrelseordförande vid årsstämma
som ska hållas i Cellaviva AB den 18 februari...
Diamyd Medical plans first interim report from the study DIAGNODE-1 where the diabetes vaccine Diamyd® is administered directly into lymph nodes
20 janv. 2016 02h32 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced in
its first quarterly report for the fiscal year 2015/2016 that a first six month
interim report for DIAGNODE-1, a...
Diamyd Medical planerar första delrapport från studien DIAGNODE-1, där diabetesvaccinet Diamyd® ges direkt i lymfnod, i kvartal 1 2016
20 janv. 2016 02h32 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar idag i sin första
kvartalssrapport för räkenskapsåret 2015/2016 att en första sexmånaders
delrapport från DIAGNODE-1, en klinisk...
Delårsrapport I 15/16
20 janv. 2016 02h30 HE
|
Diamyd Medical AB (publ)
september 2015 – november 2015
Diamyd Medical AB (publ), räkenskapsåret 2015/2016
Perioden 1 september 2015 – 30 november 2015
· Periodens resultat uppgick till -4,3 (-5,9) MSEK
· Resultat per...
Quarterly Report I 15/16
20 janv. 2016 02h30 HE
|
Diamyd Medical AB (publ)
September 2015 – November 2015
Diamyd Medical AB (publ), Fiscal year 2015/2016
Reporting period, September 1, 2015 – November 30, 2015
· Net result amounted to MSEK -4.3 (-5.9)
· Net result per...
Diamyd Medical plans first interim report from open label pilot study EDCR IIa with the diabetes vaccine Diamyd® in the first quarter of 2016
22 déc. 2015 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced
that a first six month interim report comprising five patients treated with
etanercept and the diabetes vaccine Diamyd® is...